CD274 and non-small cell lung carcinoma: In patients with NSCLC of squamous and non-squamous histology bearing a PD-L1 expression >50% an improved efficacy for a monotherapy with pembrolizumab compared to a platinum-based chemotherapy was observed and thus became the standard of care for these patients.